Editors Highlights—October 2026

Abstract

The treatment of inflammatory skin diseases has moved from broad immunosuppression toward mechanism‐based therapy with targeted biologics and small molecules. Psoriasis exemplifies this shift: interleukin‐23 (IL‐23)/T helper 17 (Th17) blockade can achieve near‐complete clearance, yet persistent tissue‐resident memory T cells may sustain disease memory and drive relapse after treatment withdrawal. The papers highlighted in this issue link tissue memory, genotype, treatment durability, and pathway‐directed therapy across different skin diseases. Together, they emphasize that precision dermatology must look beyond visible clearance toward biological remission and durable disease control.